Investor Overview

Who is Organovo?
  • We are a biotechnology company pioneering a unique set of therapeutic and drug profiling capabilities based on our revolutionary ability to 3D bioprint tissues that emulate human biology and disease.
  • We are developing in vivo liver tissues to treat a range of rare, life-threatening diseases, for which there are few current treatment options other than organ transplantation.
  • We are capitalizing on our foundational ability to isolate highly specialized human cells to build robust, functional human tissues by creating a range of novel preclinical in vitro disease modeling platforms.
  • We are striving to change the face of medicine by enabling translational drug discovery and through clinical development of novel approaches to treating disease.
2018 Annual Report Investor Presentation

Stock Information
ONVO (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) - 0.01 (0.91%)
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: ONVO.O.  Currently trading at $1.09 with a 52 week high of $2.09 and a 52 week low of $0.91.
Recent Investor News
Organovo to Present New Preclinical Data on 3D Bioprinted Human Liver Tissues for the Treatment of Tyrosinemia I at the Liver Meeting® 2018 (AASLD)
Organovo to Present at 2018 Cell & Gene Meeting on the Mesa
Investor Events
There are currently no events scheduled.
Featured Reports
2018 Annual Report
2018 Proxy Statement
Latest Tweets
Print Page Print Page | E-mail Page Email Page | RSS Feeds RSS Feeds | IR Contacts Investor Contacts | Financial Tear Sheet Financial Tear Sheet